Overall Scorecard: EquiTrak Pro
Product: EquiTrak Pro
MedBalance GmbH · 🇩🇪 · Class IIb (EU) · Balance & Vestibular Diagnostics
Product Score
88/100
Manufacturer Score
82/100
Regulatory Score
74/100
Risk Score
71/100
(lower is higher risk)
Overall Score
84/100
Weighted average across all dimensions
AI Recommendation
PROCEED
EquiTrak Pro presents a high-quality opportunity for Taevas Life Sciences. Clinical evidence is strong (B+ grade), manufacturer credibility is excellent (CE/ISO). Main risk is CDSCO India timeline — recommend setting deal milestones that allow registration to proceed in parallel with distribution negotiations.
Human Decision
Awaiting human decision
AI Scorecard Breakdown
| Dimension | Sub-score | Weight | Weighted | Notes |
|---|---|---|---|---|
| Clinical Relevance | 88 | 25% | 22 | Grade B+ evidence, 3 RCTs |
| Market Fit | 91 | 25% | 22.75 | India & UAE strong |
| Regulatory Pathway | 74 | 20% | 14.8 | Hindi IFU blocker |
| Competitive Position | 82 | 15% | 12.3 | Low competition in India |
| Financial Viability | 79 | 15% | 11.85 | Margins meet threshold |
| TOTAL | 84/100 | |||
Key Signals
Competitor activity in UAE Cochlear segment increased 40% — recommend accelerating timeline.